Labcorp Oncology's Medical Affairs Team explore the evolving role of HER2 overexpression in various solid tumors and discuss how advancements in Antibody Drug Conjugates, particularly T-DXd, are transforming treatment strategies in solid malignancies. They also highlight the challenges in HER2 testing across pan-solid tumors and the potential of NGS and AI algorithms to enhance diagnostic accuracy.

• Download

Published in: Frontiers in Oncology